CN104487568B - 人胚胎干细胞衍生的间充质样干细胞、方法及其应用 - Google Patents

人胚胎干细胞衍生的间充质样干细胞、方法及其应用 Download PDF

Info

Publication number
CN104487568B
CN104487568B CN201380036985.7A CN201380036985A CN104487568B CN 104487568 B CN104487568 B CN 104487568B CN 201380036985 A CN201380036985 A CN 201380036985A CN 104487568 B CN104487568 B CN 104487568B
Authority
CN
China
Prior art keywords
mscs
cells
msc
stem cells
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380036985.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN104487568A (zh
Inventor
王小方
徐仁和
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhuhai Hengqin Aimusitan Biotechnology Co Ltd
Original Assignee
Imstem Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imstem Biotechnology Inc filed Critical Imstem Biotechnology Inc
Publication of CN104487568A publication Critical patent/CN104487568A/zh
Application granted granted Critical
Publication of CN104487568B publication Critical patent/CN104487568B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/135—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/165—Vascular endothelial growth factor [VEGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/235—Leukemia inhibitory factor [LIF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2529/00—Culture process characterised by the use of electromagnetic stimulation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201380036985.7A 2012-07-11 2013-07-11 人胚胎干细胞衍生的间充质样干细胞、方法及其应用 Active CN104487568B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261670192P 2012-07-11 2012-07-11
US61/670,192 2012-07-11
US201261684509P 2012-08-17 2012-08-17
US61/684,509 2012-08-17
PCT/US2013/050077 WO2014011881A2 (en) 2012-07-11 2013-07-11 Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof

Publications (2)

Publication Number Publication Date
CN104487568A CN104487568A (zh) 2015-04-01
CN104487568B true CN104487568B (zh) 2017-08-15

Family

ID=49916687

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380036985.7A Active CN104487568B (zh) 2012-07-11 2013-07-11 人胚胎干细胞衍生的间充质样干细胞、方法及其应用

Country Status (7)

Country Link
US (4) US9725698B2 (https=)
EP (1) EP2872619B1 (https=)
JP (1) JP6277187B2 (https=)
CN (1) CN104487568B (https=)
AU (1) AU2013290146B2 (https=)
CA (2) CA2876512C (https=)
WO (1) WO2014011881A2 (https=)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106434527A (zh) 2006-04-14 2017-02-22 安斯泰来再生医药协会 血管瘤集落形成细胞
US20170114323A1 (en) 2014-06-19 2017-04-27 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
US20160095885A1 (en) * 2014-10-01 2016-04-07 WibiWorks Therapeutics, Inc. Induction Medium & Methods for Stem Cell Culture & Therapy
US20180355319A1 (en) * 2015-08-07 2018-12-13 Kyoto Prefectural Public University Corporation Method for preparing brown adipocyte
KR101779932B1 (ko) * 2015-09-15 2017-09-21 주식회사 스템랩 나노그(Nanog)를 도입한 양수 내 태아 유래 중간엽 줄기세포를 이용한 육모 촉진용 조성물의 제조방법
CN105326864A (zh) * 2015-11-30 2016-02-17 奥思达干细胞有限公司 一种治疗系统性红斑狼疮的干细胞制剂及其制备方法
WO2017100498A1 (en) 2015-12-11 2017-06-15 The Johns Hopkins University Isolation of fusion-competent myoblasts and therapeutic applications thereof related to muscular dystrophy
CN105754936B (zh) * 2016-02-25 2018-06-08 付清玲 人诱导性多能干细胞诱导为间充质干细胞的方法
US11174461B2 (en) * 2016-03-16 2021-11-16 Cynata Therapeutics Limited Colony forming medium and use thereof
CN105769911A (zh) * 2016-03-23 2016-07-20 中国人民解放军第二军医大学 间充质干细胞诱导斑秃处毛发再生的方法及应用
US20200140851A1 (en) * 2016-08-23 2020-05-07 The Scripps Research Institute Methods and Compositions Related to In Vivo Selection of Functional Molecules
KR101971322B1 (ko) * 2016-10-17 2019-04-23 사회복지법인 삼성생명공익재단 Ｓｏｃｓ의　발현　또는　활성　억제를　이용한　고효능 줄기세포 선별방법
KR101971323B1 (ko) * 2016-10-17 2019-04-23 사회복지법인 삼성생명공익재단 면역질환 치료를 위한 고효능 줄기세포 선별방법
CN108121161A (zh) * 2016-11-26 2018-06-05 中国科学院大连化学物理研究所 一种高通量形成拟胚体的微阵列芯片的制备方法与应用
WO2018119213A1 (en) * 2016-12-23 2018-06-28 StemBios Technologies, Inc. Use of somatic stem cells for decreasing il-6 level
CN106754715A (zh) * 2017-02-13 2017-05-31 四川新生命干细胞科技股份有限公司 一种用于造血干细胞培养的滋养层的制备方法
WO2018170390A1 (en) * 2017-03-17 2018-09-20 Senti Biosciences, Inc. Immunomodulating cell circuits
KR20180112547A (ko) * 2017-04-04 2018-10-12 경북대학교 산학협력단 역분화 줄기세포의 지속적인 계대배양을 통한 중간엽 줄기세포로의 분화방법
WO2018191619A1 (en) 2017-04-13 2018-10-18 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
WO2018218105A1 (en) * 2017-05-26 2018-11-29 Kite Pharma, Inc. Methods of making and using embryonic mesenchymal progenitor cells
US11547730B2 (en) 2017-05-26 2023-01-10 Steminent Biotherapeutics Inc. Therapy for polyglutamine (polyQ) diseases
US11773376B2 (en) 2017-07-13 2023-10-03 National University Corporation Tokyo Medical And Dental University Artificial tendon or ligament tissue produced using three-dimensional mechanosignaling cell culture system
CN107460169B (zh) * 2017-07-14 2020-12-11 中国科学院广州生物医药与健康研究院 维生素c在制备培养基中的用途
CN111849899B (zh) * 2017-07-28 2022-06-14 杨涛 定向诱导hiPSC分化为神经细胞体系的诱导培养基
CN109666630A (zh) * 2017-10-17 2019-04-23 澳门大学 多能干细胞分化为间充质干细胞的方法及其培养基和应用
CA3080691C (en) * 2017-11-10 2022-11-15 Regenesis Science Co., Ltd. Method for producing cultured cell, and method for producing therapeutic agent for spinal cord injury disease
WO2019104466A1 (en) * 2017-11-28 2019-06-06 Harvatek Corporation Methods of producing populations of mesenchymal stem cells from peripheral blood and uses thereof
CN108324993B (zh) * 2018-01-15 2020-11-03 朱剑虹 一种诱导毛发再生的干细胞复合体、其制备方法及应用
CN108570448B (zh) * 2018-01-26 2019-04-02 皓昇莱生物制药有限公司 一种高效的hPSCs向MSCs分化的方法
CN108570447A (zh) * 2018-01-26 2018-09-25 皓昇莱生物制药有限公司 一种筛选分化hPSCs向MSCs的方法
TW201938788A (zh) * 2018-03-06 2019-10-01 美商歐瑞３恩公司 用於軟骨修復之源自iPSC之細胞組合物及相關系統與方法
CN110295145B (zh) * 2018-03-22 2020-10-16 苏州麦迪耐斯医药科技有限公司 一种体外培养脑肿瘤细胞的培养液及培养方法
CN108504627A (zh) * 2018-04-02 2018-09-07 中国人民解放军陆军军医大学第二附属医院 人类黄韧带干细胞的提取方法
CN108498452A (zh) * 2018-04-10 2018-09-07 上海交通大学医学院附属仁济医院 一种用于治疗勃起功能障碍的含干细胞可注射水凝胶及其制备方法
KR20240033089A (ko) * 2018-06-06 2024-03-12 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 신경 줄기 세포 조성물 및 신경변성 장애를 치료하는 방법
CN109055307B (zh) * 2018-08-26 2021-06-11 杭州爱唯生命科技有限公司 一种bmp-2激活剂及在干细胞诱导分化方面的应用
AU2019359890B2 (en) 2018-10-17 2024-10-24 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
CN110352951A (zh) * 2018-11-15 2019-10-22 崔磊 一种无血清无dmso组织工程骨冻存液及其制备和冻存方法
CN109536444B (zh) * 2018-12-11 2022-06-28 吉林省拓华生物科技有限公司 一种适用于恶性实体瘤肿瘤浸润t淋巴细胞的分离诱导方法
CN113518635A (zh) * 2018-12-17 2021-10-19 哈佛学院院长等 用于调节免疫系统的生物工程化支架及其用途
JP7628499B2 (ja) * 2019-02-27 2025-02-10 武田薬品工業株式会社 同種異系療法のための改良された幹細胞集団
US20200318113A1 (en) * 2019-03-05 2020-10-08 MiRagen Therapeutics, Inc. Polynucleotide conjugates and uses thereof
AU2020284114B2 (en) * 2019-05-31 2025-06-26 Fibrobiologics, Inc. Concurrent activation of regenerative and tolerogenic processes by fibroblast-based compositions for the treatment of multiple sclerosis
AU2020293287A1 (en) * 2019-06-14 2022-01-06 FUJIFILM Cellular Dynamics, Inc. Methods for the production of multiple lineages from induced pluripotent stem cells using charged surfaces
CN112094804B (zh) * 2019-06-18 2024-05-14 中国医学科学院基础医学研究所 一种异质性干细胞群、其制备方法及用途
EP4004191A4 (en) * 2019-07-26 2022-10-12 Brexogen Inc. Precursor cells of induced pluripotent stem cell-derived mesenchymal stem cells and method for preparing the same
CN110499282B (zh) * 2019-09-03 2021-05-11 广州赛莱拉干细胞科技股份有限公司 一种培养基及其应用和诱导肌腱干细胞向脂肪细胞分化的方法
CN110713973B (zh) * 2019-09-30 2021-05-14 浙江大学 一种诱导多能干细胞分化为间充质干细胞的培养基组合及方法
CN110862983B (zh) * 2019-11-05 2021-04-06 桂林医学院 一种特异靶向小鼠Gdf5基因的sgRNA导向序列及其应用
CN115087730A (zh) * 2019-11-28 2022-09-20 香港大学 间充质基质细胞作为ipsc诱导的重编程来源
CN113018316A (zh) * 2019-12-24 2021-06-25 厦门大学 多能干细胞来源的间充质干细胞在修复皮肤损伤中的应用
CN111454892A (zh) * 2020-03-12 2020-07-28 成都世联康健生物科技有限公司 牙间充质干细胞培养基及在牙髓干细胞内的活性验证方法
CN111471648A (zh) * 2020-04-10 2020-07-31 南京大学 一种预处理活化的间充质干细胞的制备方法及其在髓系白血病治疗中的应用
TW202208613A (zh) * 2020-05-05 2022-03-01 美商加速生物科學有限公司 非永生的多潛能幹細胞
TWI806051B (zh) * 2020-05-13 2023-06-21 長聖國際生技股份有限公司 生產類紅血球及/或紅血球之方法
WO2021232062A1 (en) * 2020-05-13 2021-11-18 Figene, Llc Fibroblast based therapy for treatment of parkinson's disease
CN111557952A (zh) * 2020-05-28 2020-08-21 澳门大学 间充质干细胞在制备用于促进脂肪移植的制剂中的应用
WO2022016165A2 (en) * 2020-06-02 2022-01-20 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Differentiation of trophectoderm lineage cells from pluripotent stem cells
US20230250394A1 (en) * 2020-06-24 2023-08-10 Syracuse University Generation of perinatal-like mesenchymal stem cells from human induced pluripotent stem cells
WO2022004938A1 (ko) * 2020-06-30 2022-01-06 주식회사 미래셀바이오 유사 중간엽 줄기세포의 제조방법
CN112359012B (zh) * 2020-10-22 2022-11-25 中国科学院水生生物研究所 诱导多能干细胞分化制备心脏瓣膜内皮细胞的方法及其应用
CN114504596A (zh) * 2020-10-23 2022-05-17 厦门大学 多能干细胞来源的间充质干细胞在治疗银屑病中的应用
CN113462642A (zh) * 2021-08-12 2021-10-01 呈诺再生医学科技(珠海横琴新区)有限公司 间充质干细胞的快速诱导分化方法、试剂盒及其应用
WO2023090589A1 (ko) * 2021-11-22 2023-05-25 주식회사 미래셀바이오 전분화능 줄기세포 기반 과민성 면역반응에 의한 피부질환의 예방 또는 치료용 조성물
CN113975298A (zh) * 2021-11-29 2022-01-28 海南康盾生物制药有限公司 一种用于小儿自闭症的细胞治疗药物及其制备方法
CN114438037B (zh) * 2022-01-25 2024-06-04 深圳市乐土生物医药有限公司 一种制备诱导性间充质干细胞的方法
CN114574436A (zh) * 2022-05-06 2022-06-03 深圳汉盛汇融再生医学科技有限公司 一种治疗膝关节退行性病变的干细胞制剂及其制备方法
CN115785221B (zh) * 2022-07-11 2023-07-04 北京大学 一种转录因子hoxb9磷酸化位点的特异性抗体及其制备方法和应用
EP4689077A2 (en) * 2023-03-31 2026-02-11 Pluristyx, Inc. Conditionally immortalized stem cells and uses thereof
CN116376828B (zh) * 2023-06-02 2023-08-11 成都云测医学生物技术有限公司 一种诱导CD4+T细胞生成Treg细胞的方法及应用
WO2025221594A1 (en) * 2024-04-16 2025-10-23 The Regents Of The University Of California Methods for generating dopaminergic neurons and organoids thereof
CN120009537B (zh) * 2025-02-14 2025-12-26 上海安库生医生物科技有限公司 Tacstd2蛋白在制备检测和鉴定人羊膜上皮细胞的产品中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102317442A (zh) * 2008-12-17 2012-01-11 斯克里普斯研究所 干细胞的产生和保持

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3654090A (en) 1968-09-24 1972-04-04 Organon Method for the determination of antigens and antibodies
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5981180A (en) 1995-10-11 1999-11-09 Luminex Corporation Multiplexed analysis of clinical specimens apparatus and methods
CA2306501C (en) 1997-10-14 2011-03-29 Luminex Corporation Precision fluorescently dyed particles and methods of making and using same
ATE239801T1 (de) 1998-01-22 2003-05-15 Luminex Corp Mikropartikel mit multiplen fluoreszenz-signalen
EP1108011A2 (en) 1998-06-08 2001-06-20 Osiris Therapeutics, Inc. In vitro maintenance of hematopoietic stem cells
US6384105B1 (en) 1999-04-16 2002-05-07 William Marsh Rice University Poly(Propylene Fumarate) cross linked with Poly(Ethylene Glycol)
US6355699B1 (en) 1999-06-30 2002-03-12 Ethicon, Inc. Process for manufacturing biomedical foams
NZ535243A (en) * 2002-03-15 2008-05-30 Wicell Res Inst Inc Method for generating primate trophoblasts
WO2006091766A2 (en) * 2005-02-24 2006-08-31 Jau-Nan Lee Human trophoblast stem cells and use thereof
EP1937801A1 (en) * 2005-09-02 2008-07-02 Agency for Science, Technology and Research Method of deriving mesenchymal stem cells
US20090304647A1 (en) * 2008-05-30 2009-12-10 The Board Of Trustees Of The University Of Illinois Production of Neural Stem Cells from Bone Marrow Tissue and Use Thereof
JP2010094062A (ja) 2008-10-15 2010-04-30 Saitama Medical Univ 間葉系幹細胞の多分化能維持用培地、培養方法、及び分化方法
WO2010124290A2 (en) * 2009-04-24 2010-10-28 Whitehead Institute For Biomedical Research Compositions and methods for deriving or culturing pluripotent cells
WO2011019092A1 (en) * 2009-08-12 2011-02-17 Kyoto University Method for inducing differentiation of pluripotent stem cells into neural precursor cells
KR101193541B1 (ko) 2009-08-24 2012-10-22 한국과학기술원 인간 배아줄기세포에서 중간엽 줄기세포로 분화시키는 방법
WO2012068170A2 (en) * 2010-11-15 2012-05-24 Jau-Nan Lee Generation of neural stem cells from human trophoblast stem cells
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
SI2785359T1 (sl) 2011-11-30 2018-11-30 Astellas Institute For Regenerative Medicine Mezenhimske stromalne celice in uporabe povezane z njimi

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102317442A (zh) * 2008-12-17 2012-01-11 斯克里普斯研究所 干细胞的产生和保持

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
辐射对骨髓间充质干细胞增殖分化及相关基因表达的影响;徐小雅,金慰芳,高建军,周轶,盛辉;《辐射研究与辐射工艺学报》;20090430;第27卷(第2期);第111-114页 *

Also Published As

Publication number Publication date
US20210085725A1 (en) 2021-03-25
CA3176706A1 (en) 2014-01-16
JP6277187B2 (ja) 2018-02-07
AU2013290146B2 (en) 2018-01-18
EP2872619A4 (en) 2016-03-02
US10226488B2 (en) 2019-03-12
US20150191699A1 (en) 2015-07-09
EP2872619A2 (en) 2015-05-20
JP2015523083A (ja) 2015-08-13
US20190167733A1 (en) 2019-06-06
WO2014011881A3 (en) 2014-04-03
HK1208055A1 (en) 2016-02-19
US20170290864A1 (en) 2017-10-12
US10842826B2 (en) 2020-11-24
CN104487568A (zh) 2015-04-01
CA2876512C (en) 2022-12-13
CA2876512A1 (en) 2014-01-16
EP2872619B1 (en) 2018-02-14
AU2013290146A1 (en) 2015-02-05
WO2014011881A2 (en) 2014-01-16
US9725698B2 (en) 2017-08-08

Similar Documents

Publication Publication Date Title
CN104487568B (zh) 人胚胎干细胞衍生的间充质样干细胞、方法及其应用
US12209255B2 (en) Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
Bieback et al. Mesenchymal stromal cells from umbilical cord blood
JP6266726B2 (ja) 放射線照射または化学物質による傷害を治療するための方法
Harrell et al. Therapeutic potential of amniotic fluid derived mesenchymal stem cells based on their differentiation capacity and immunomodulatory properties
JP2022078044A (ja) コロニー形成培地及びその使用
JP2019535691A (ja) 間葉系幹細胞集団、それらの生成物およびそれらの使用
Kerrigan et al. Stem cell therapy of gliomas
US20080138319A1 (en) Bone-marrow derived neurogenic cells and uses thereof
WO2024019962A1 (en) Methods of treating brain injury
HK1208055B (en) Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
HK1136846A1 (en) Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
HK1136846B (en) Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
HK1162600A (en) Production of oligodendrocytes from placenta-derived stem cells

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1208055

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20170907

Address after: Guangdong city of Zhuhai province Hengqin Baohua Road No. 6, room 105, -22584 (central office)

Patentee after: Zhuhai Hengqin Aimusitan Biotechnology Co. Ltd.

Address before: American Connecticut

Patentee before: IMSTEM BIOTECHNOLOGY INC.

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1208055

Country of ref document: HK